Guardion Health Sciences retains Atlantra to explore strategic alternatives

Guardion Health Sciences has retained Alantra as its financial advisor to assist with the strategic review and transaction process. Robert Weingarten, the Chairman of the Board of Directors of Guardion, stated, "We do not believe that the current market valuation of the Company accurately reflects the potential value of the Company and our clinical nutrition platform and brand. As fiduciaries on behalf our stockholders, the Guardion Board of Directors has been aggressively exploring a diverse range of strategic options over the past several months to enhance stockholder value. Our near-term objective is to identify and analyze strategic transactional opportunities, including a sale of the Company and/or its Viactiv brand, that would be expected to deliver enhanced value to stockholders. In this regard, we have engaged with Alantra, which has demonstrated a substantial record of experience and success in achieving significant results for clients in the Company’s industry, and we are looking forward to working with the Alantra team to achieve our objectives". The Board of Directors has not set a timetable for the strategic review process, nor has it made any decisions related to any further actions or potential strategic alternatives at this time. There can be no assurances that this process will result in a transaction, or that if a transaction is completed, that it will ultimately enhance stockholder value. The Company does not intend to provide periodic updates until the Board of Directors determines that disclosure is appropriate and/or necessary under the circumstances.